A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory …

KS Bauer, JE Karp, TS Garimella, S Wu, M Tan… - Leukemia research, 2005 - Elsevier
This study was conducted to define the maximum tolerated dose (MTD), dose limiting
toxicity (DLT), and pharmacokinetics of idarubicin when administered with and without the P-…

N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma

…, ZM Shao, XS Li, JV Ordonez, BA Conley, S Wu… - …, 1995 - academic.oup.com
Retinoid response pathways involve retinoic acid receptors (RARs) and retinoid X receptors.
N-(4-hydroxyphenyl) retinamide (4-HPR), a derivative of all-trans-retinoic acid (RA) is …

Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis

…, LA Doyle, B Hassel, Y Wei, KS Bauer, S Wu… - Molecular …, 2003 - ASPET
To evaluate the function and substrate specificity of human breast cancer resistance protein
(BCRP, ABCG2) in the absence of cofactors or heterologous partner proteins, Xenopus …

Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics

…, R Sridhara, R Finley, R Hemady, S Wu… - Cancer chemotherapy …, 1997 - Springer
A phase I trial of all-trans-retinoic acid (ATRA) was conducted to establish the maximum
tolerable dose (MTD) of ATRA given once daily to patients with solid tumors. Cancer patients for …

IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells

…, X Cheng, TE Fandy, RK Srivastava, S Wu… - Molecular cancer …, 2006 - AACR
Multiple myeloma is an incurable disease for the majority of patients, therefore requiring new
biological targeted therapies. In primary myeloma cells, IMP dehydrogenase (IMPDH) was …

Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive …

…, B Goldspiel, D Venzon, D Danforth, S Wu… - Journal of Clinical …, 2000 - ascopubs.org
PURPOSE: N-(4-hydroxyphenyl) retinamide ([4-HPR], Fenretinide; RW Johnson Pharmaceutical
Research Institute, Springhouse, PA) and tamoxifen (TAM) have synergistic antitumor …

Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by …

…, ZM Shao, XS Li, M Dawson, AM Jetten, S Wu… - Journal of Biological …, 1994 - ASBMB
Retinoids mediate their actions via RARs (retinoic acid receptors) and RXRs (retinoid X
receptors). Each class of these nuclear retinoid receptors is further subdivided into three species, …

Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients

N Takebe, X Cheng, S Wu, K Bauer, OG Goloubeva… - Clinical cancer …, 2004 - AACR
Purpose: Inosine monophosphate dehydrogenase (IMPDH) inhibitors have been used to
induce leukemia blast cell differentiation but have not been tested in multiple myeloma for …

Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors

MJ Edelman, KS Bauer Jr, S Wu, R Smith, S Bisacia… - Clinical cancer …, 2007 - AACR
Purpose: Based on preclinical data showing synergy between 7-hydroxystaurosporine (UCN-01)
and platinum agents, a phase I trial of carboplatin with UCN-01 administered as a 3 h …

Phase I Trial of All-Trans Retinoic Acid in Patients with Treated Head and Neck Squamous Carcinoma

…, M Sutharalingam, RG Smith, DA Van Echo, S Wu… - Clinical Cancer …, 2000 - AACR
Although retinoids show promise for prevention of second primary upper aerodigestive tract
tumors, the optimum retinoid, dose, and schedule are unknown. All-trans retinoic acid (ATRA…